PER-041-00
Completed
未知
Change from Haloperidol to Olanzapine in schizophrenic patients: an open study
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- -F20
- Sponsor
- ELI LILLY INTERAMERICA INC.,
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Women or men, from 18 to 65 years of age in the visit 1\.
- •Female patients with gestational potential should use a medically accepted means of contraception.
- •Each patient must have a sufficient level of understanding to communicate intelligently with the researcher, nurse and study coordinator.
- •Patients must be reliable. They must agree to cooperate with all the tests and exams required by the protocol.
- •Each patient (or authorized legal representative of the patient) must understand the nature of the study and sign an informed consent.
- •Patients must meet the criteria for schizophrenia defined in the DSMIV.
- •Patients must have been treated with haloperidol for a minimum of 6 weeks before entering the study.
- •Patients must have a total SAS score of\> 3\.
Exclusion Criteria
- •Women who are pregnant or nursing.
- •Severe illnesses, including hepatic, renal, gastroenterological, respiratory, cardiovascular (including ischemic heart disease), endocrinological, neurological, immunological or hematological diseases, such as anticipating hospitalization within 3 months or death within 3 years.
- •Hyperthyroidism or hyperthyroidism uncorrected.
- •Acute angle glaucoma.
- •One or more attacks without a clear and determined etiology. Leukopenia or history of leukopenia without a clear and determined etiology.
- •History of severe allergies or adverse reactions to multiple medications.
- •Abuse or dependence of any substance (alcohol or other drugs) within the previous 3 months.
- •Judged clinically as seriously at risk of suicide.
- •Participation in a clinical trial of another research substance within 1 month (30 days) before entering the study (visit 1\).
- •Any other medication concomitant with primary activity of the central nervous system, different from that specified in section 3\.8\.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
OLANZAPINE VERSUS HALOPERIDOL IN THE TREATMENT OF ACUTE MANIAPER-038-99ELI LILLY INTERAMERICA INC.,
Completed
Not Applicable
OLANZAPINE VERSUS ZIPRASIDONE IN THE TREATMENT OF SCHIZOPHRENIA-F20F20PER-066-01ELI LILLY INTERAMERICA INC.,
Recruiting
Phase 2
Comparison the effect of Olanzapine and Haloperidol on the treatment of delirium in ICU in Valiasr hospitalIRCT20141209020258N114Arak University of Medical Sciences50
Terminated
Phase 4
Clozapine Versus Haloperidol for Treating the First Episode of SchizophreniaSchizophreniaNCT00169091Harvard Medical School (HMS and HSDM)32
Recruiting
Phase 3
Comparison of olanzapine and haloperidol and quetiapine on deliriumDelirium.Delirium due to known physiological conditionIRCT20200927048852N1Arak University of Medical Sciences90